Sanofi-Aventis S.A. ADR (SNY) Stock Price, Quote & News

Company Profile

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscienti...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 33 1 53 77 40 00

Website: www.sanofi.com

Address:

46, avenue de la Grande ArmEe, Paris, France

ajbski Sep. 12 at 2:51 PM

$NVAX HEB, CVS, Walgreens, and Walmart pharmacies offer the Nuvaxovid (Novavax) COVID-19 vaccine. $SNY

0 · Reply

Quantumup Sep. 11 at 10:32 AM

JPMorgan🏁 $DNTH Overweight-$135 and said -- DNTH is a clinical-stage biotech developing therapeutics for severe autoimmune diseases led by claseprubart, an active-C1s inhibitor, with an initial focus on complement-mediated neuromuscular disorders. $SNY $ARGX AZN UCBJY Here's what JPMorgan went on to say in its initiation report: https://x.com/Quantumup1/status/2098358983132058013?s=20

0 · Reply

Woodman7 Sep. 9 at 2:47 PM

$BIIB $CLNN $QNTM $RHHBY $SNY From the article: “Clene Inc. (NASDAQ: CLNN) shared results from new analyses examining clinical outcomes among CNM-Au8(R)-treated patients whose neurofilament light chain (“NfL”) biomarker levels declined or stabilized. These findings will be included in Clene’s planned New Drug Application (“NDA”) seeking accelerated approval and are intended to address the questions raised by the U.S. Food and Drug Administration (“FDA”) during a March 2026 Type C meeting. At that meeting, the FDA acknowledged that NfL, a recognized blood marker of nerve-cell injury, has established prognostic value in amyotrophic lateral sclerosis (“ALS”) and could potentially serve as a reasonably likely surrogate endpoint to support accelerated approval.”

0 · Reply

JackedNicholson Sep. 8 at 1:07 PM

$ALT Who is most likely to sign a deal with Altimmune? $SNY $MRK $NVO

1 · Reply

NetworkNewsWire Sep. 8 at 1:04 PM

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach $QNTM $SNY $RHHBY $BIIB $CLNN https://ibn.fm/MrHnd

0 · Reply

ajbski Sep. 8 at 12:43 AM

$NVAX 🚨New publication: Vaccine Volume 92, 24 October 2026, 129034: “The platform trial in COVID-19 priming and BOOsting (PICOBOO): The reactogenicity of nine licensed COVID-19 vaccines delivered in immunocompetent adults”. 🟡 One of the key findings: Reactogenicity was consistently lowest after Nuvaxovid compared to mRNA vaccines. $SNY $PFE $MRNA https://www.sciencedirect.com/science/article/abs/pii/S0264410X26008431?via%3Dihub

1 · Reply

Docdavid Sep. 7 at 5:30 PM

$SNY

0 · Reply

JackedNicholson Sep. 7 at 1:18 PM

$ALT • $SNY • $NVO • $MRK

0 · Reply

grampslol Sep. 5 at 7:21 PM

$MNKD 31 Vice Presidents... 1 flop drug , afrezza dpi inhaled prandial insulin approved in 2014 ... the only insulin with the FDA black box warning label dumped by $SNY over a decade ago ... $JNJ $LLY $LQDA

2 · Reply

ToRni27 Sep. 5 at 1:21 AM

$SNY Sanofi you got to do something about it! When? The problem is getting bigger and bigger for you every single day! Buyout your competitors in fabry disease or be obsolet soonTM and write off 1 bn + us dollar in revenues per year and growing! $PLX

0 · Reply

Market Cap	103.69B
Revenue (ttm)	52.85B
Net Income (ttm)	8.84B
EPS (ttm)	N/A
PE Ratio	8.72
Forward PE	8.43
Profit Margin	16.72%
Debt to Equity Ratio	0.31

Volume	2,373,000
Avg Vol	2,821,568
Day's Range	N/A - N/A
Shares Out	2.42B
Stochastic %K	13%
Beta	0.35
Analysts	Sell
Price Target	$52.61